

From: Love, Jane M. [<mailto:JLove@gibsondunn.com>]

Sent: Friday, August 04, 2017 1:00 PM

To: Trials <Trials@USPTO.GOV>

Cc: Love, Jane M. <JLove@gibsondunn.com>; Trenchard, Robert W. <RTrenchard@gibsondunn.com>; Rea, Teresa <TRea@crowell.com>; Yellin, Deborah <DYellin@crowell.com>; Lentz, Shannon <SLentz@crowell.com>; Parmelee, Steve <sparmelee@wsgr.com>; Rosato, Michael <mrosato@wsgr.com>; 'Mills, Jad' <jmills@wsgr.com>

Subject: IPR2017-00854 and IPR2017-01550

Re: IPR2017-00854 and IPR2017-01550

To the Patent Trial and Appeal Board:

We represent Patent Owner Novartis in these IPRs. We write to inform the Board that Novartis does not object to Argentum's Motion for Joinder of IPR2017-01550 with now-instituted IPR2017-00854, as Argentum's Petition in the 01550 IPR is substantively the same as the Petition in the 00854 IPR, and Argentum has agreed not to pursue any arguments or make any filings separate from those made by the Petitioner in the 00854 IPR. We accordingly respectfully request that the Board grant Argentum's joinder motion, and Novartis hereby agrees not to submit any Preliminary Response to Argentum's Petition. Novartis instead will proceed with a Patent Owner Response to the Petitions in both IPRs simultaneously.

Respectfully submitted,

Jane Love (Lead Counsel) and Robert Trenchard (Backup Counsel)

Jane M. Love, Ph.D.

GIBSON DUNN

Gibson, Dunn & Crutcher LLP
200 Park Avenue, New York, NY 10166-0193
Tel +1 212.351.3922 • Fax +1 212.351.6322
JLove@gibsondunn.com • www.gibsondunn.com